

# Shuyi Si

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10477080/publications.pdf>

Version: 2024-02-01

53  
papers

2,558  
citations

279701

23  
h-index

189801

50  
g-index

56  
all docs

56  
docs citations

56  
times ranked

3607  
citing authors

#	ARTICLE	IF	CITATIONS
1	The novel ER stress inducer Sec C triggers apoptosis by sulfating ER cysteine residues and degrading YAP via ER stress in pancreatic cancer cells. <i>Acta Pharmaceutica Sinica B</i> , 2022, 12, 210-227.	5.7	10
2	Ginkgolic acid and anacardic acid are reversible inhibitors of SARS-CoV-2 3-chymotrypsin-like protease. <i>Cell and Bioscience</i> , 2022, 12, 65.	2.1	4
3	E17241 as a Novel ABCA1 (ATP-Binding Cassette Transporter A1) Upregulator Ameliorates Atherosclerosis in Mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, e284-e298.	1.1	8
4	Screening and Identification of a Novel Anti-tuberculosis Compound That Targets Deoxyuridine 5â€²-Triphosphate Nucleotidohydrolase. <i>Frontiers in Microbiology</i> , 2021, 12, 757914.	1.5	2
5	Development of a simple and miniaturized sandwich-like fluorescence polarization assay for rapid screening of SARS-CoV-2 main protease inhibitors. <i>Cell and Bioscience</i> , 2021, 11, 199.	2.1	26
6	Bistachybotryns Lâ€™V, bioactive phenylspirodrimane dimers from the fungus <i>Stachybotrys chartarum</i> . <i>Organic Chemistry Frontiers</i> , 2020, 7, 531-542.	2.3	11
7	Rutaecarpine derivative R3 attenuates atherosclerosis via inhibiting NLRP3 inflammasomeâ€™related inflammation and modulating cholesterol transport. <i>FASEB Journal</i> , 2020, 34, 1398-1411.	0.2	21
8	Identification of a Compound That Inhibits the Growth of Gram-Negative Bacteria by Blocking BamAâ€™BamD Interaction. <i>Frontiers in Microbiology</i> , 2020, 11, 1252.	1.5	20
9	A small-molecule inhibitor of PCSK9 transcription ameliorates atherosclerosis through the modulation of FoxO1/3 and HNF1â€™. <i>EBioMedicine</i> , 2020, 52, 102650.	2.7	36
10	Myeloperoxidase Controls Bone Turnover by Suppressing Osteoclast Differentiation Through Modulating Reactive Oxygen Species Level. <i>Journal of Bone and Mineral Research</i> , 2020, 36, 591-603.	3.1	16
11	Identification and characterization of Zika virus NS5 RNA-dependent RNA polymerase inhibitors. <i>International Journal of Antimicrobial Agents</i> , 2019, 54, 502-506.	1.1	28
12	Cytotoxic metabolites from the endophytic fungus <i>Chaetomium globosum</i> 7951. <i>RSC Advances</i> , 2019, 9, 16035-16039.	1.7	13
13	A Novel Small Molecule Which Increases Osteoprotegerin Expression and Protects Against Ovariectomy-Related Bone Loss in Rats. <i>Frontiers in Pharmacology</i> , 2019, 10, 103.	1.6	5
14	Isocoumarindole A, a Chlorinated Isocoumarin and Indole Alkaloid Hybrid Metabolite from an Endolichenic Fungus <i>Aspergillus</i> sp.. <i>Organic Letters</i> , 2019, 21, 1530-1533.	2.4	58
15	Identification of an anti-Gram-negative bacteria agent disrupting the interaction between lipopolysaccharide transporters LptA and LptC. <i>International Journal of Antimicrobial Agents</i> , 2019, 53, 442-448.	1.1	27
16	A novel piperidine identified by stem cell-based screening attenuates pulmonary arterial hypertension by regulating BMP2 and PTGS2 levels. <i>European Respiratory Journal</i> , 2018, 51, 1702229.	3.1	18
17	Identification of TB-E12 as a novel FtsZ inhibitor with anti-tuberculosis activity. <i>Tuberculosis</i> , 2018, 110, 79-85.	0.8	11
18	A novel SIRT1 activator E6155 improves insulin sensitivity in type 2 diabetic KKAy mice. <i>Biochemical and Biophysical Research Communications</i> , 2018, 498, 633-639.	1.0	12

#	ARTICLE	IF	CITATIONS
19	E3317 promotes cholesterol efflux in macrophage cells via enhancing ABCA1 expression. <i>Biochemical and Biophysical Research Communications</i> , 2018, 504, 68-74.	1.0	6
20	SIRT1 activator E1231 protects from experimental atherosclerosis and lowers plasma cholesterol and triglycerides by enhancing ABCA1 expression. <i>Atherosclerosis</i> , 2018, 274, 172-181.	0.4	18
21	Identification of a Novel Liver X Receptor Agonist that Regulates the Expression of Key Cholesterol Homeostasis Genes with Distinct Pharmacological Characteristics. <i>Molecular Pharmacology</i> , 2017, 91, 264-276.	1.0	29
22	Suberanilohydroxamic Acid as a Pharmacological Kruppel-Like Factor 2 Activator That Represses Vascular Inflammation and Atherosclerosis. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	49
23	Three structurally-related impurities in norvancomycin drug substance. <i>Journal of Antibiotics</i> , 2017, 70, 158-165.	1.0	6
24	Improving the N-terminal diversity of sansanmycin through mutasynthesis. <i>Microbial Cell Factories</i> , 2016, 15, 77.	1.9	17
25	E17110 promotes reverse cholesterol transport with liver X receptor $\hat{1}^2$ agonist activity in vitro. <i>Acta Pharmaceutica Sinica B</i> , 2016, 6, 198-204.	5.7	12
26	Identification of trichostatin derivatives from <i>Streptomyces</i> sp. CCCC 203909. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 562-565.	1.0	13
27	microRNA-185 modulates low density lipoprotein receptor expression as a key posttranscriptional regulator. <i>Atherosclerosis</i> , 2015, 243, 523-532.	0.4	60
28	Identification of a novel partial agonist of liver X receptor $\hat{1}\pm$ (LXR $\hat{1}\pm$ ) via screening. <i>Biochemical Pharmacology</i> , 2014, 92, 438-447.	2.0	19
29	Optimization of Rutaecarpine as ABCA1 Up-Regulator for Treating Atherosclerosis. <i>ACS Medicinal Chemistry Letters</i> , 2014, 5, 884-888.	1.3	30
30	Rutaecarpine suppresses atherosclerosis in ApoE $\hat{0}/\hat{0}$ mice through upregulating ABCA1 and SR-BI within RCT. <i>Journal of Lipid Research</i> , 2014, 55, 1634-1647.	2.0	53
31	Identification of anti-tuberculosis agents that target the cell-division protein FtsZ. <i>Journal of Antibiotics</i> , 2014, 67, 671-676.	1.0	23
32	Identification of a Mutant $\hat{1}\pm$ Na/K-ATPase That Pumps but Is Defective in Signal Transduction. <i>Journal of Biological Chemistry</i> , 2013, 288, 13295-13304.	1.6	55
33	Expression of Mutant $\hat{1}\pm$ Na/K-ATPase Defective in Conformational Transition Attenuates Src-mediated Signal Transduction*. <i>Journal of Biological Chemistry</i> , 2013, 288, 5803-5814.	1.6	41
34	The Mechanism of Action of Bufalin in Inhibition of Lipid Droplet Accumulation in Mouse Macrophages. <i>Biological and Pharmaceutical Bulletin</i> , 2013, 36, 364-369.	0.6	1
35	Salvianolic acid B inhibits macrophage uptake of modified low density lipoprotein (mLDL) in a scavenger receptor CD36-dependent manner. <i>Atherosclerosis</i> , 2012, 223, 152-159.	0.4	72
36	A Series of Beta-Carboline Derivatives Inhibit the Kinase Activity of PLKs. <i>PLoS ONE</i> , 2012, 7, e46546.	1.1	33

#	ARTICLE	IF	CITATIONS
37	Two Thiophenes Compounds Are Partial Peroxisome Proliferator-Activated Receptor .ALPHA./GAMMA. Dual Agonists. <i>Biological and Pharmaceutical Bulletin</i> , 2011, 34, 1631-1634.	0.6	6
38	Identification of Dehydroxytrichostatin A as a Novel Up-Regulator of the ATP-Binding Cassette Transporter A1 (ABCA1). <i>Molecules</i> , 2011, 16, 7183-7198.	1.7	15
39	Discovery of Antagonists for Human Scavenger Receptor CD36 via an ELISA-Like High-Throughput Screening Assay. <i>Journal of Biomolecular Screening</i> , 2010, 15, 239-250.	2.6	47
40	Identification of two antagonists of the scavenger receptor CD36 using a high-throughput screening model. <i>Analytical Biochemistry</i> , 2010, 400, 207-212.	1.1	15
41	How can high-throughput screening deliver drugs to treat atherosclerosis?. <i>Expert Opinion on Drug Discovery</i> , 2010, 5, 1175-1188.	2.5	5
42	DH166, a beta-carboline derivative, inhibits the kinase activity of PLK1. <i>Cancer Biology and Therapy</i> , 2009, 8, 2374-2383.	1.5	51
43	Identification of trichostatin A as a novel transcriptional up-regulator of scavenger receptor BI both in HepG2 and RAW 264.7 cells. <i>Atherosclerosis</i> , 2009, 204, 127-135.	0.4	28
44	The Molecular Target of Rubimailin in the Inhibition of Lipid Droplet Accumulation in Macrophages. <i>Biological and Pharmaceutical Bulletin</i> , 2009, 32, 1317-1320.	0.6	6
45	Sansanmycins B and C, New Components of Sansanmycins. <i>Journal of Antibiotics</i> , 2008, 61, 237-240.	1.0	49
46	Identification of Upregulators of Human ATP-Binding Cassette Transporter A1 via High-Throughput Screening of a Synthetic and Natural Compound Library. <i>Journal of Biomolecular Screening</i> , 2008, 13, 648-656.	2.6	35
47	Molecular Target of Piperine in the Inhibition of Lipid Droplet Accumulation in Macrophages. <i>Biological and Pharmaceutical Bulletin</i> , 2008, 31, 1063-1066.	0.6	36
48	Identification of Novel Human High-Density Lipoprotein Receptor Up-regulators Using a Cell-Based High-Throughput Screening Assay. <i>Journal of Biomolecular Screening</i> , 2007, 12, 211-219.	2.6	17
49	A New Nucleosidyl-peptide Antibiotic, Sansanmycin. <i>Journal of Antibiotics</i> , 2007, 60, 158-161.	1.0	70
50	The association of dynamin 2 with Rac1 plays an important role in NAD(P)H oxidase activation by angiotensin II in vascular smooth muscle cells. <i>FASEB Journal</i> , 2007, 21, A1149.	0.2	0
51	Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. <i>Nature Medicine</i> , 2004, 10, 1344-1351.	15.2	1,200
52	Beauveriolides, Specific Inhibitors of Lipid Droplet Formation in Mouse Macrophages, Produced by <i>Beauveria</i> sp. FO-6979.. <i>Journal of Antibiotics</i> , 1999, 52, 1-6.	1.0	57
53	Structure Elucidation of Fungal Beauveriolide III, a Novel Inhibitor of Lipid Droplet Formation in Mouse Macrophages.. <i>Journal of Antibiotics</i> , 1999, 52, 7-12.	1.0	58